Showing posts with label cancer. Show all posts
Showing posts with label cancer. Show all posts

Sunday, October 12, 2014

Replication stress links structural and numerical cancer chromosomal instability

7:59 PM Posted by sandmann , , , No comments
At the recent "Tumor heterogeneity: Implications for targeted Therapy" conference, Charles Swanton (London Research Institute) presented how kidney, colon and lung tumors change and evolve over time. This work was published in a series of high-profile papers, including two back-to-back articles in Science this week. Here, I review a part of the talk with results published in Burrell et al in Nature in 2013.

In 2013, Swanton and co-workers examined why many tumors display chromosomal instability (CIN). While normal human cells are diploid and carry two copies of each gene, cancer cells from many solid tumors often accumulate specific regions and loose others. This can e.g. lead to the loss of tumor suppressor genes and provides genetic variation that can fuel the evolution of sub-clones.

The balanced inheritance of genetic material is tightly controlled in normal cells, but seems to be error-prone in many human cancers. For example, colorectal cancer can broadly be categorized into chromosomal-stable (CIN-) and -unstable (CIN+) subtypes. Swanton an co-workers set out to understand the mechanisms specifically destabilizing CIN+ colorectal tumors.

Through careful microscopy imaging of dividing cells, they documented a high frequency of DNA replication artifacts in CIN+ cell lines. These cells seemed unable to duplicate their genome correctly before cell division and produced e.g. chromosomal fragments without centromers, which were randomly distributed to the daughter cells. The root of the problems appeared to be a disruption of the DNA replication process itself, as the authors noticed that the replication forks in CIN+ cells progressed at a slower pace than in their CIN- counterparts. This is a sign of "replication stress", which was previously shown to cause DNA damage and chromosomal aberrations.

What could cause replication stress in colorectal cancers ? To formulate specific hypotheses, Swanton and co-workers compared the cancer genomes of CIN+ and CIN- tumors. First, they checked known oncogenes and tumor suppressors. While the TP53 gene, which is frequently deactivated in human cancers, appeared to be more often mutated in CIN+ cases, its biological function did not explain the observed chromosomal instability.

Next, the scientists enumerated copy number variants (CNVs), looking for regions lost or gained in CIN+ but not CIN- tumors, and found a promising candidate: loss of a specific region of chromosome 18 (region 18q) was observed in 88% of aneuploid tumours and 80% of CIN+ cell lines. The researchers had detected a statistically significant correlation between 18q loss and chromosomal instability - but had they really identified a causal relationship ?

If region 18 really contained genes important for the correct execution of replication, its loss should precede the onset of chromosomal instability. During colon cancer development, cells typically progress through a precursor stage, called adenoma, before progressing into malignant carcinomas.

Vogelgram Overview
A genetic model for colorectal tumorigenesis, Fearon & Vogelstein, Cell, 1990; Image source: Wikimedia Commons

Both 18q loss and chromosomal instability were found to be less frequent in adenomas than carcinoma samples from the same patients, consistent with a causal relationship between these two observations (but not proving it).

To elucidate the molecular consequences of 18q loss, the researchers systematically deactivated all of the protein-coding genes contained in this region of the genome. Targeting any one of three genes - PIGN, MEX3C or ZNF516 - produced a CIN+ phenotype in cell lines including acentric chromosomes and anaphase bridges, activation of the DNA damage response and reduced replication fork speed. In addition, just like the naturally observed CIN+ phenotype, the consequences of inactivating these genes could be prevented by supplying additiona DNA building blocks in the form of nucleosides to the cells.

Conclusions:
Recurrent loss of a specific genomic region, 18q, in colorectal cancers may be responsible for disrupting the normal replication process in cancer cells. This could trigger a cascade of subsequent losses or gains, increasing the genetic heterogeneity in the following generations of cancer cells and accelerate the emergence of resistance.

References

Thursday, October 9, 2014

Clone wars

7:51 AM Posted by sandmann , , No comments
At the Tumor Heterogeneity: Implications for Targeted Therapy conference in Stanford on October 6th, 2014, Kornelia Polyak (Harvard Medical School) described how her lab used fluorescence in situ hybridization (iFISH) and allele-specific PCR-FISH (STAR-FISH) to image copy number variation and point-mutations of breast cancer at the single-cell level. She highlighted how treatment with anti-HER2 antibodies induced changes in the composition of tumors in a breast cancer cohort, including a  post-treatment enrichment of PI3K mutant cells.

 
To understand how clonal heterogeneity is maintained over time and study the role of interactions between clones, her lab performed xenograft experiments with combinations of cell lines engineered to over-express different non-cell autonomous drivers. Polyclonal tumors, containing a mixture of cell lines, grew faster than clonal xenografts and produced metastases earlier.

Among many other findings, the researchers found that IL11 expression by even a small number of cells in the xenograft increased its density of blood vessels. This promoted growth of the tumor as a whole, including that of the other sub-clones, providing direct experimental evidence for interactions between clonal sub-populations.

As pointed out during the lively discussion, these experiments focused on selected secreted signaling molecules and did not investigate the competitiveness of well-known driver oncogenes such as e.g. mutant KRAS. (KRAS mutant cell lines grew too fast to be included in the xenograft experiment.)

References:

Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity; Marusyk et al, Nature, 2014

Tumor Heterogeneity: Implications for targeted therapy

7:43 AM Posted by sandmann , No comments
Earlier this week, I had the chance to attend the "Tumor Heterogeneity: Implications for targeted therapy" conference at the Stanford Cancer Institute. (For a 6 min, 17 s summary of the topic, listen to Simon Tavare on ABC's Science Show.) Cancer is a complex disease - and tumors from different patients, multiple tumors from the same patient and even separate parts of the same tumor can look and behave markedly differently.
Treatment induces a bottleneck effect, where only some resistant sub-clones will survive and propagate to re-form a heterogeneous tumor. (Source: Wikipedia, by Lcchong - Own work. Licensed under Creative Commons Attribution-Share Alike 3.0 Unported license via Wikimedia Commons.)
For example, as Kimberly Allison (Stanford) pointed out, pathologist routinely look at breast cancer samples under the microscope to assess whether a tumor expresses high or low levels of the HER2 (ERBB2) protein. They struggle with summarizing what they see in a single score, because they frequently observe regions with high and low levels of HER2 in the same section.

The conference provided a broad range of topics, including technologies to characterize tumors at the single-cell level, the study of tumor evolution and clinical reports from physicians. Here are some of the main points I took away:
  • late stage tumors contain many sub-clones, differing e.g. in the numbers and types of genetic lesions as well as response to treatment
  • the degree of heterogeneity within a tumor is itself prognostic, e.g. more heterogeneity is often associated with a worse outcome
  • subset of cells already carry mutations causing resistance to any specific cancer drug, and their expansion is associated with recurrence after single-agent therapy
  • every tumor follows a unique evolutionary path, starting with early 'trunk' mutations followed by branching into sub-clones, which may compete, cooperate or simply co-exist.
  • new technologies to detect tumors and characterize them over time, e.g. through blood draws during the course of treatment, offer opportunities to study the dynamics of cancer progression
  • recent advances in the field of cancer immunotherapy, e.g. alerting the patient's immune cells to the presence of a tumor, may offer new therapeutic opportunities

In the coming days, I will summarize a few of my personal highlights from this meeting.